RecruitingPhase 3Other
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Sponsored by Definium Therapeutics US, Inc.
NCT ID
NCT07592689
Target Enrollment
165 participants
Start Date
2026-05-10
Est. Completion
2028-06
About This Study
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
Conditions Studied
Interventions
- •Placebo
- •DT120
Eligibility
Age:18 Years - 74 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: 1. Diagnosis of MDD per DSM-5 2. Male or female aged 18 to 74 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration 4. MADRS Total Score ≥26 5. CGI-S Score ≥4 Exclusion Criteria: 1. Certain psychiatric disorders (other than major depressive disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine 4. Any clinically significant unstable illness
Study Locations (27)
Lighthouse Psychiatry
Gilbert, Arizona, United States
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Kadima Neuropsychiatry Institute
San Diego, California, United States
UCSF Department of Neurology
San Francisco, California, United States
Psychedelic Science Institute
Santa Monica, California, United States
Mountain View Clinical Research, Inc
Denver, Colorado, United States
K2 Medical Research (Maitland)
Maitland, Florida, United States
Charter Research
Orlando, Florida, United States
K2 Medical Research (Tampa)
Tampa, Florida, United States
CenExel Atlanta
Atlanta, Georgia, United States
+17 more locations